Literature DB >> 31974826

Plasma exchange combined with bortezomib-based chemotherapy is effective for early renal recovery in a patient with IgD-λ type multiple myeloma.

Hiroyuki Ueda1, Hideaki Kuno2, Daisuke Takahashi2, Ai Katsuma2, Ai Kimura2, Akio Nakashima2, Junichiro Kato2, Mamiko Momoki3, Rie Ohba3, Nobuaki Dobashi3, Izumi Yamamoto2, Tetsuya Kawamura2, Yoichi Miyazaki2, Takashi Yokoo2.   

Abstract

The immunoglobulin (Ig) D type is a rare variant of multiple myeloma (MM), that accounts for 1-2% of all cases. Compared to the more common types of MM, IgD MM is known to have more severe symptoms at presentation, and a poorer prognosis. A woman was admitted to our hospital for severe acute kidney disease and disorder (AKD) and back pain, and was started on hemodialysis. The renal biopsy revealed light chain cast nephropathy. She was diagnosed with IgD-λ MM based on Bence-Jones protein expression and high IgD serum levels, and started bortezomib therapy with plasma exchange (PE). After three sessions of PE, the serum free light chain levels decreased by 92%, and she was withdrawn from dialysis. The patient underwent autologous transplantation and is still in remission, demonstrating the benefits of a bortezomib-based regimen in combination with PE for IgD MM with AKD.

Entities:  

Keywords:  Acute kidney disease and disorder; IgD-Multiple myeloma; Plasma exchange; Renal recovery

Mesh:

Substances:

Year:  2020        PMID: 31974826      PMCID: PMC7148401          DOI: 10.1007/s13730-020-00448-y

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  15 in total

1.  Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial.

Authors:  Frank Bridoux; Pierre-Louis Carron; Brigitte Pegourie; Eric Alamartine; Karine Augeul-Meunier; Alexandre Karras; Bertrand Joly; Marie-Noëlle Peraldi; Bertrand Arnulf; Cécile Vigneau; Thierry Lamy; Alain Wynckel; Brigitte Kolb; Bruno Royer; Nolwenn Rabot; Lotfi Benboubker; Christian Combe; Arnaud Jaccard; Bruno Moulin; Bertrand Knebelmann; Sylvie Chevret; Jean-Paul Fermand
Journal:  JAMA       Date:  2017-12-05       Impact factor: 56.272

2.  Prognostic factors in IgD myeloma: a study of 21 cases.

Authors:  W E Fibbe; J Jansen
Journal:  Scand J Haematol       Date:  1984-11

3.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

4.  Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies.

Authors:  Samih H Nasr; Anthony M Valeri; Sanjeev Sethi; Mary E Fidler; Lynn D Cornell; Morie A Gertz; Martha Lacy; Angela Dispenzieri; S Vincent Rajkumar; Robert A Kyle; Nelson Leung
Journal:  Am J Kidney Dis       Date:  2012-03-13       Impact factor: 8.860

5.  The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.

Authors:  M A Dimopoulos; M Roussou; M Gkotzamanidou; N Nikitas; E Psimenou; D Mparmparoussi; C Matsouka; M Spyropoulou-Vlachou; E Terpos; E Kastritis
Journal:  Leukemia       Date:  2012-07-05       Impact factor: 11.528

6.  Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases.

Authors:  J Bladé; J A Lust; R A Kyle
Journal:  J Clin Oncol       Date:  1994-11       Impact factor: 44.544

7.  Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents.

Authors:  Flora Zagouri; Efstathios Kastritis; Argiris S Symeonidis; Nikolaos Giannakoulas; Eirini Katodritou; Sosana Delimpasi; Panagiotis Repousis; Evangelos Terpos; Meletios A Dimopoulos
Journal:  Eur J Haematol       Date:  2014-01-26       Impact factor: 2.997

8.  Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients.

Authors:  Laure Ecotière; Antoine Thierry; Céline Debiais-Delpech; Sylvie Chevret; Vincent Javaugue; Estelle Desport; Simohamed Belmouaz; Nathalie Quellard; Sihem Kaaki; Jean Michel Goujon; Jean-Paul Fermand; Guy Touchard; Frank Bridoux
Journal:  Nephrol Dial Transplant       Date:  2015-08-19       Impact factor: 5.992

Review 9.  Unusual myelomas: a review of IgD and IgE variants.

Authors:  Shivlal Pandey; Robert A Kyle
Journal:  Oncology (Williston Park)       Date:  2013-08       Impact factor: 2.990

10.  European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial.

Authors:  Colin A Hutchison; Mark Cook; Nils Heyne; Katja Weisel; Lucinda Billingham; Arthur Bradwell; Paul Cockwell
Journal:  Trials       Date:  2008-09-28       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.